Is LEXICON PHARMACEUTICALS, INC. a real, registered company?
LEXICON PHARMACEUTICALS, INC. is a registered filer with the SEC (CIK 1062822) and has filed since 2023-06-20. 2 filings are on record, the latest on 2026-02-17.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
How much has LEXICON PHARMACEUTICALS, INC. raised?
Its new offerings report $127.88M sold across 2 offerings, as its own filings state.
Run the free check on LEXICON PHARMACEUTICALS, INC. →
The Woodlands, TEXAS
Pharmaceuticals
2
$127.88M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-02-17 | New offering first sale 2026-02-02 | $55.67M | $59.15M | SEC filing |
| 2023-06-20 | New offering first sale 2023-06-05 | $72.22M | $72.22M | SEC filing |
Keep reading
More on LEXICON PHARMACEUTICALS, INC. and the records around it.
LEXICON PHARMACEUTICALS, INC. elsewhere on the record
- 5%+ stake filings Nov 2026
- Form D filing Feb 2026
- Layoff notices Nov 2024
- Who owns it
Companies that share a holder
- Invus, L.P. also filed stake reports on 24 other companies: DBV Technologies S.A. (Nov 2026), Rani Therapeutics Holdings, Inc. (Nov 2026), Silence Therapeutics plc (Nov 2026)
- FMR LLC also filed stake reports on 762 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch LEXICON PHARMACEUTICALS, INC.
Get an email when LEXICON PHARMACEUTICALS, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with LEXICON PHARMACEUTICALS, INC.?
Who to contact
- Raymond Debbane — Director
- Phillipe Amouyal — Director
- Samuel Barker — Director
- Ivan Cheung — Director
- Scott Coiante — Executive Officer
- Brian Crum — Executive Officer
- Lisa DeFrancesco — Executive Officer
- Mike Exton — Executive Officer, Director
- Rachel Martens — Executive Officer
- Suma Gopinathan — Executive Officer
- Craig Granowitz — Executive Officer
- Rachel Martens — Executive Officer
- Wendy McDermott — Executive Officer
- Christopher Sobecki — Director
- Diane Sullivan — Director
- Judith Swain — Director
- Round: Form D filed 2026-02-17
- Amount sold: $55.67M
- Industry: Pharmaceuticals
- Based: The Woodlands, TEXAS
People listed
- Raymond Debbane — Director
- Phillipe Amouyal — Director
- Samuel Barker — Director
- Ivan Cheung — Director
- Scott Coiante — Executive Officer
- Brian Crum — Executive Officer
- Lisa DeFrancesco — Executive Officer
- Mike Exton — Executive Officer, Director
- Rachel Martens — Executive Officer
- Suma Gopinathan — Executive Officer
- Craig Granowitz — Executive Officer
- Rachel Martens — Executive Officer
- Wendy McDermott — Executive Officer
- Christopher Sobecki — Director
- Diane Sullivan — Director
- Judith Swain — Director
- Filing: Form D filed 2026-02-17
- Amount sold: $55.67M
- Industry group: Pharmaceuticals
- Based: The Woodlands, TEXAS
- Entity type: Corporation
We'll show it in your MentionFox inbox when LEXICON PHARMACEUTICALS, INC. raises, hires or launches. No email unless you switch it on.
Watch LEXICON PHARMACEUTICALS, INC. →Want the whole picture on LEXICON PHARMACEUTICALS, INC.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on LEXICON PHARMACEUTICALS, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on LEXICON PHARMACEUTICALS, INC. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from LEXICON PHARMACEUTICALS, INC.'s own filings with the SEC. The people those filings name are on the team page.
